AESKU Diagnostics, one of the companies participating in a genomic medicine consortium in Buffalo and Manhattan, does not develop a test to help in the diagnosis of psoriasis. An article in Friday’s News incorrectly listed psoriasis among the autoimmune diseases targeted by AESKU.
The Buffalo News corrects published errors of substance. To request a correction, please notify the editor by writing to: P.O. Box 100, Buffalo, NY 14240. Or call The News at 849-4444 and ask to speak to the editor of the department in which the article was published. Or email email@example.com or fax your request to 856-5150.